Inovio stock down as FDA accepts BLA for INO-3107, but notes insufficient info for accelerated approval pathway. Meeting ...

Shares of Inovio Pharmaceuticals INO jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for ...

Inovio Pharmaceuticals ( ($INO) ) has provided an announcement. On December 29, 2025, INOVIO announced that the U.S. Food and Drug Administration ...

Investing.com -- Inovio Pharmaceuticals Inc (NASDAQ:INO) stock plunged 21% Monday after the FDA raised concerns about the company’s accelerated approval pathway for its RRP treatment candidate.

Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash ...

Inovio Pharmaceuticals Inc. closed 41.59% below its 52-week high of $2.98, which the company achieved on September 9th.

As of Wednesday, December 24, Inovio Pharmaceuticals, Inc.’s INO share price has surged by 5.13%, which has investors questioning if this is right time to sell.

Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Monday, November 10, 2025.

PLYMOUTH MEETING, Pa. (AP) — PLYMOUTH MEETING, Pa. (AP) — Inovio Pharmaceuticals Inc. (INO) on Monday reported a loss of $45.5 million in its third quarter. On a per-share basis, the Plymouth Meeting, ...

This was the stock's second consecutive day of losses.